Aeglea BioTherapeutics Investor Presentation Deck
Capitalization
As of 6/20/2023*
Shares of common stock outstanding
Pre-funded warrants
Merger consideration
Shares of common
Shares of preferred
Preferred conversion ratio
Total pre-financing common equivalent
Concurrent financing
Shares of preferred
Common equivalent
Total capitalization (Common)
2.6 million
1.2 million
0.5 million
0.4 million
1:40
18.9 million
0.7 million
28.9 million
47.7 million
ā
Shares of common stock and preferred stock
were issued to Spyre Therapeutics Inc. security
holders in exchange for all of Spyre's outstanding
equity interests.
Shares of preferred stock were issued to Spyre
Therapeutics Inc. stockholders and to investors in
the $210 million private placement.
Each share of preferred stock will automatically
convert into 40 shares of common stock upon
stockholder approval, subject to certain beneficial
ownership restrictions set by each holder.
Please refer to the company's SEC filings for
additional information.
*Note: All figures have been retroactively adjusted to reflect the company's 1-for-25 reverse stock split that will be effective as of 12:01 a.m. Eastern Time on September 8, 2023.
SPYRE
38View entire presentation